Fundamental Analysis of Gilead Sciences Inc - Growth / Value Index
GILD - Valuation Highlights
Valuation Analysis
Undervalued - Price to Intrinsic Value of 0.274
Book Value in last 3 years is trending up
Tsr Value Index - Poor Score of 25.00
Price to Earning Ratio is 53.85 and EV to EBITDA is 65.39 suggesting that it is very expensive
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | 53.91 | 14.50 | -22.10 % | |
| Price to Book | 2.57 | 3.74 | -6.93 % | 4.84 |
| Price to Sales | 3.09 | 3.11 | -0.717 % | |
| Enterprise Value to EBITDA Multiple | 65.44 | 11.16 | -25.45 % |
GILD - Profitability Highlights
Profitability Analysis
Piotroski F Score - Excellent Value of 8.0
Over the last 3 years, the company has achieved Incredible Return on Equity
Company Earning excess return
Reasonable Dividend Yield of 4.67 %
Good Return On Capital Employed of 12.19
Tsr Profitability Index - Very Poor Score of 9.38
EPS decline for last four quarters
Negative Net Margin MRQ
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | 9.38 | 25.83 | 19.47 % | -23.89 |
| Return On Asset | 3.24 | 9.46 | 30.12 % | -7.41 |
| Net Profit Margin | 5.74 | 21.45 | 27.45 % | -62.37 |
| Operating Profit Margin | 5.75 | 43.54 | 62.06 % | -64.64 |
| EBITDA Margin | 5.75 | 34.05 | 30.88 % | -64.64 |
Highlights
| Market Cap | 84368.96 M |
| Enterprise Value | 103270 M |
| Price/Book TTM | 2.57 |
| Outstanding Share | 1245.85 M |
| Float/ Outstanding Share | 99.79% |
| Dividend Yield | 4.54 % |
Share Holding
Guru Numbers
| Price/Graham No | 3.00 |
| Peter Lynch Ratio | 0.527 |
| Piotroski F Score | 8.00 |
| Altman Z Score | 2.54 |
| Sloan Ratio | -0.0042 |
| Peter Lynch Fair Value | 0 |
GILD - Growth Highlights
Growth Analysis
Annual sales of the company is increased for three years in a row
Tsr Growth Index - Very Poor Score of 18.93
Company's Total Assets is Decreasing for last 3 years
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 27451.00 M | 0.403 % | 6.03 % |
| Gross Profit | 27451.00 M | 0.171 % | 6.03 % |
| EBITDA | 1578.00 M | 31.40 % | 368.11 % |
| Net Profit | 1576.00 M | 27.96 % | 391.81 % |
| EPS | 1.26 | 28.37 % | NA |
GILD - Stability Highlights
Stability Analysis
Debt to equity ratio has decreased and is lowest in last three years
Company financial liquidity has improved
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 1.10 | -10.97 % | 1.44 |
| Cash Ratio | 0.747 | 31.49 % | |
| Quick Ratio | 1.16 | 5.09 % | 0.721 |
| Shareholders Equity | 36.62 | 8.91 % | |
| Debt to EBITDA | 2.68 | -27.43 % |
Historical Valuation Ratios of Gilead Sciences Inc
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Gilead Sciences Inc
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Gilead Sciences Inc
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Gilead Sciences Inc
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)